OPT / Opthea Limited - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

EX-99.1

Appendix 4E Preliminary Final Report Opthea Limited ABN 32 006 340 567 YEAR ENDED JUNE 30, 2025 RESULTS FOR ANNOUNCEMENT TO THE MARKET June 30, 2025 US$ (000’s) June 30, 2024 US$ (000’s) Movement % Results Revenues from ordinary activities 5,557 3,520 Up 57.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

CORPORATE UPDATEINVESTOR CALL – 20 August 2025 Dr Jeremy Levin – Chairman of the Board Fred Guerard – Chief Executive Officer Tom Reilly – Chief Financial Officer

CORPORATE UPDATE INVESTOR CALL – 20 August 2025 Dr Jeremy Levin – Chairman of the Board Fred Guerard – Chief Executive Officer Tom Reilly – Chief Financial Officer This investor presentation (Presentation) is dated August 19th, 2025 and has been prepared by Opthea Limited (ASX:OTP) (Opthea or the Company).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Provides Corporate Update Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman an

Exhibit 99.1 ASX, Nasdaq and Media Release August 18, 2025 Opthea Provides Corporate Update Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st Melbourne, Australia Tuesday 19

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release August 19, 2025 Announcement Summary Entity name OPTHEA LIMITED Announcement Type New announcement Date of this announcement Tuesday August 19, 2025 The +securities to be quoted are: Other Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. Securities issues as part of

Opthea Provides Corporate Update Four members of the Board of Directors to depart as of June 2nd, 2025 Dr Julia Haller, Dr Susan Orr, Mr Quinton Oswald and Mr Anshul Thakral to step down

Exhibit 99.1 ASX, Nasdaq and Media Release June 2, 2025 Opthea Provides Corporate Update Four members of the Board of Directors to depart as of June 2nd, 2025 Dr Julia Haller, Dr Susan Orr, Mr Quinton Oswald and Mr Anshul Thakral to step down Melbourne, Australia, and Princeton, N.J., 2 June 2025 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), today provided a corporate update followi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Provides Corporate Update Reduction in force of approximately 65% to preserve cash Opthea estimates cash and cash equivalents of US$100M as of March 2025

Exhibit 99.1 ASX, Nasdaq and Media Release April 10, 2025 Opthea Provides Corporate Update Reduction in force of approximately 65% to preserve cash Opthea estimates cash and cash equivalents of US$100M as of March 2025 Melbourne, Australia, and Princeton, N.J., 10 April 2025 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”) today provided a corporate update following the termination of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe t

Exhibit 99.1 ASX, Nasdaq and Media Release March 31, 2025 Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Fu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and o

Exhibit 99.1 ASX, Nasdaq and Media Release March 24, 2025 Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern Melbourne, Australia, and Princeton, N.J., 24 March, 2025 -

Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina

Exhibit 99.1 ASX, Nasdaq and Media Release March 3, 2025 Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina Melbourne, Australia and Princeton, NJ, March 3, 2025 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25)

Exhibit 99.1 ASX, Nasdaq and Media Release February 28, 2025 Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) Melbourne, Australia, and Princeton, NJ, US, February 28, 2025 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Com

Results for announcement to the markets Financial report: iii Director’s Report Additional Business and Operational Updates Auditor’s Independence Declaration Financial Statements Notes to the Condensed Consolidated Financial Statements Forward‑Looki

February 28, 2025 Half‑Year Financial Report – December 31, 2024 In accordance with Listing Rule 4.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea Completes Drug Product PPQ Campaign Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026

Exhibit 99.1 ASX, Nasdaq and Media Release February 26, 2025 Opthea Completes Drug Product PPQ Campaign Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 Melbourne, Australia, and Princeton, NJ, US, February 26, 2025 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea Completes COAST Final Week 52 Patient Visit COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25

Exhibit 99.1 ASX, Nasdaq and Media Release February 18, 2025 Opthea Completes COAST Final Week 52 Patient Visit COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25 Melbourne, Australia, and Princeton, NJ, US, February 18, 2025 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea to Present at Oppenheimer Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release February 7, 2025 Opthea to Present at Oppenheimer Healthcare Conference Melbourne, Australia, and Princeton, NJ, US, February 7, 2025 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular

Opthea Wet AMD Data Featured at Macula Society Meeting

EX-99.1 2 opt-ex991.htm PRESS RELEASE Exhibit 99.1 ASX, Nasdaq and Media Release February 6, 2025 Opthea Wet AMD Data Featured at Macula Society Meeting Melbourne, Australia, and Princeton, NJ, US, February 6, 2025 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal disea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LI

6-K 1 opt-optheawetamd.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Disclaimer and Forward-looking Statements This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”)

Transforming Patient Outcomes with Superior Vision Gains Investor Event | New York City | January 28, 2025 NASDAQ (OPT); ASX (OPT.

Disclaimer and Forward-looking Statements This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”)

Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | January 2025 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea to Host Investor Days in New York and Australia Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Fe

Exhibit 99.1 ASX, Nasdaq and Media Release January 8, 2025 Opthea to Host Investor Days in New York and Australia Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 Melbourne, Australia, and Princeton, NJ, US, January 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea Announces Publication in Diabetic Macular Edema Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translation

Exhibit 99.1 ASX, Nasdaq and Media Release January 7, 2025 Opthea Announces Publication in Diabetic Macular Edema Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational Vision Science & Technology and included in the Anti-VEGF Special Journal Issue of ARVO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California

Exhibit 99.1 ASX, Nasdaq and Media Release December 19, 2024 Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California Melbourne, Australia, and Princeton, NJ, US, December 19, 2024 - Opthea Limited (ASX/NASDAQ:OPT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

Exhibit 99.1 ASX, Nasdaq and Media Release November 26, 2024 Opthea’s Wet AMD Program to be Featured at FLORetina 2024 Melbourne, Australia, and Princeton, NJ, US, November 26, 2024 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea to Participate in Citi 2024 Global Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release November 25, 2024 Opthea to Participate in Citi 2024 Global Healthcare Conference Melbourne, Australia, and Princeton, NJ, US, November 25, 2024 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-rela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Disclaimer and Forward-looking Statements This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”)

Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | November 2024 NASDAQ (OPT); ASX (OPT.

Resolution details

Exhibit 99.3 ASX, Nasdaq and Media Release November 15, 2024 Market Announcements Office Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000 Dear Ms., Results of 2024 Annual General Meeting Opthea Limited(ASX: OPT) In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each re

Opthea Receives A$15.9 Million R&D Tax Incentive

Exhibit 99.4 ASX, Nasdaq and Media Release November 15, 2024 Opthea Receives A$15.9 Million R&D Tax Incentive Melbourne, Australia and Princeton, NJ, US, November 15, 2024 – Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular dege

Opthea Appoints Kathy Connell to Board of Directors Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025

Exhibit 99.2 ASX, Nasdaq and Media Release November 15, 2024 Opthea Appoints Kathy Connell to Board of Directors Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 Melbourne, Australia, and Princeton, NJ, US, November 15, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a cli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea Chairman’s Address to the 2024 Annual General Meeting

Exhibit 99.1 ASX, Nasdaq and Media Release November 15, 2024 Opthea Chairman’s Address to the 2024 Annual General Meeting Melbourne, Australia, and Princeton, NJ, US, November 15, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), Good morning to those of you who have joined us from Australia and good afternoon to our US shareholders. On behalf of the board and management team, I am

OPT / Opthea Limited - Depositary Receipt (Common Stock) / REGAL FUNDS MANAGEMENT PTY LTD - AMENDMENT NO.5 Passive Investment

SC 13G/A 1 u117241sc13ga5.htm AMENDMENT NO.5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value (Title of Class of Securities) 68386J208 (CUSIP Number) July

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea’s Wet AMD Program Featured at Ophthalmology Events 17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024

Exhibit 99.1 ASX, Nasdaq and Media Release November 12, 2024 Opthea’s Wet AMD Program Featured at Ophthalmology Events 17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 Melbourne, Australia, and Princeton, NJ, US, November 12, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biophar

UPDATE -- Opthea to Participate in November Investor Conferences Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024

Exhibit 99.1 ASX, Nasdaq and Media Release November 4, 2024 UPDATE - Opthea to Participate in November Investor Conferences Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 Melbourne, Australia, and Princeton, NJ, US, November 4, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Appendix 4C

Exhibit 99.1 ASX, Nasdaq and Media Release 31 October 2024 Quarterly Activity Report Q1 FY25 Highlights • Leadership appointments to strengthen medical and commercial capabilities –Chief Financial Officer Tom Reilly, Chief Medical Officer Parisa Zamiri MD, PhD, and Chief Commercial Officer Mike Campbell • Completed drug substance PPQ campaign validating manufacturing process of sozinibercept • Joi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Disclaimer and Forward-looking Statements This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”)

Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | October 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

2023 – 2024 Notice of Meeting and Explanatory Notes A transformative treatment for wet AMD is in (SIGHT) opthea

Exhibit 99.1 2023 – 2024 Notice of Meeting and Explanatory Notes A transformative treatment for wet AMD is in (SIGHT) opthea 01 Opthea 2023 – 2024 Notice of Annual General Meeting and Explanatory Notes Notice of Annual General Meeting and Explanatory Notes Date: Friday, 15 November 2024 Time: 9:00am (Melbourne time) Location: The meeting will be held virtually via https://meetnow.global/MGVYDQ7 In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea Files Notice of Annual General Meeting Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation

Exhibit 99.1 ASX, Nasdaq and Media Release October 16, 2024 Opthea Files Notice of Annual General Meeting Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda Melbourne, Australia, and Princeton, NJ, US, October 16, 2024 - Opthea Limited (AS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea Wet AMD Program to be Presented at Innovate Retina

Exhibit 99.1 ASX, Nasdaq and Media Release October 10, 2024 Opthea Wet AMD Program to be Presented at Innovate Retina Melbourne, Australia, and Princeton, NJ, US, October 10, 2024- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketin

Exhibit 99.1 ASX, Nasdaq and Media Release October 8, 2024 Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing Melbourne, Australia, and Princeton, NJ, US, October 8, 2024- Opthea Limited (ASX/NASDAQ:

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Exhibit 99.1 ASX, Nasdaq and Media Release September 30, 2024 Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 Melbourne, Australia, and Princeton, NJ, US, September 30, 2024 - Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Introduction and Objectives Speaker: Arshad Khanani, MD, MA, FASRS

Improving on the Standard of Care in nAMD: Sponsored by Addressing the VEGF-C and -D Pathways EURetina Symposium 2024 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Opthea Joins the S&P/ASX 300 Index

Exhibit 99.1 ASX, Nasdaq and Media Release September 23, 2024 Opthea Joins the S&P/ASX 300 Index Melbourne, Australia, and Princeton, NJ, US, September 23, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Frederic Guerard, Chief Executive Officer of Opthea Limited (the “Company”), and Karen Adams, Vice President, Finance of the Company, each hereby certifies

/s/ Frederic Guerard

Exhibit 12.1 CERTIFICATIONS I, Frederic Guerard, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F/A of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mi

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-251052 on Form S-8 and Registration Statement No. 333-262444 on Form F-3 of our report dated August 30, 2024, relating to the financial statements of Opthea Limited appearing in this Annual Report on Form 20-F/A for the year ended June 30, 2024. /s/ D

/s/ Karen Adams

Exhibit 12.2 CERTIFICATIONS I, Karen Adams, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F/A of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progres

Exhibit 99.1 ASX, Nasdaq and Media Release September 18, 2024 Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 Melbourne, Australia, and P

Opthea to Have Significant Presence at the 24thEURETINA Congress and EURETINA Innovation Spotlight

Exhibit 99.1 ASX, Nasdaq and Media Release September 10, 2024 Opthea to Have Significant Presence at the 24thEURETINA Congress and EURETINA Innovation Spotlight Melbourne, Australia, and Princeton, NJ, US, September 10, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Disclaimer and Forward-looking Statements This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”)

Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | September 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Daniel Geffken and Mike Campbell respectively appointed CFO ad interim and CCO Three senior leaders appointed for Biometrics, Clinical Operations and Market Access Deepening retina and launch expertise ahead of Phase 3 topline data readouts in 2025

Exhibit 99.1 ASX, Nasdaq and Media Release September 5, 2024 Opthea Announces Executive Leadership Changes and Senior Hires Daniel Geffken and Mike Campbell respectively appointed CFO ad interim and CCO Three senior leaders appointed for Biometrics, Clinical Operations and Market Access Deepening retina and launch expertise ahead of Phase 3 topline data readouts in 2025 Melbourne, Australia, and P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princi

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release 3rd September, 2024 Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference Melbourne, Australia, and Princeton, NJ, US, September 3, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevale

/s/ Frederic Guerard

Exhibit 12.1 CERTIFICATIONS I, Frederic Guerard, certify that: 1. I have reviewed this annual report on Form 20-F of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to

Opthea Reports Full-Year Financial Results and Business Updates Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in pr

Exhibit 99.2 Opthea Reports Full-Year Financial Results and Business Updates Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept Melbourne, Australia, and Princeton, NJ, US, August 30, 2024 - Opthea Limited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

2023 – 2024 Corporate Governance Statement A transformative treatment for wet AMD is in SIGHT Logo OPTHEA

2023 – 2024 Corporate Governance Statement A transformative treatment for wet AMD is in SIGHT Logo OPTHEA Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES Corporate Governance Council recommendation Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above.

OPTHEA US INC.

Exhibit 4.17 OPTHEA US INC. October 24, 2023 Fred Guerard 8701 Acuarela Ct Austin, TX 78735 USA Re: Employment Terms Dear Fred: On behalf of OPTHEA US, INC. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which is anticipate

OPTHEA US INC.

Exhibit 4.18 OPTHEA US INC. October 24, 2023 Peter F. Lang 51 5th Avenue Apt. 10BF New York, NY 10003 Re: Employment Terms Dear Peter: On behalf of OPTHEA US, INC. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which is ant

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Frederic Guerard, Chief Executive Officer of Opthea Limited (the “Company”), and Peter Lang, Chief Financial Officer of the Company, each hereby certifies t

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-251052 on Form S-8 and Registration Statement No. 333-262444 on Form F-3 of our report dated August 30, 2024, relating to the financial statements of Opthea Limited appearing in this Annual Report on Form 20-F for the year ended June 30, 2024. Melbour

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Appendix A Explanation of Insider Trading under the US Federal Securities Laws

Exhibit 11.1 SECURITIES TRADING POLICY 1. Introduction 1.1 Securities of Opthea Limited (the “Company”) are listed on ASX and Nasdaq. 1.2 This policy outlines: (a) when directors, senior management and other employees may deal in Company Securities; and (b) procedures to reduce the risk of insider trading. 1.3 The requirements imposed by this policy are separate from, and in addition to, the legal

OPTHEA LIMITED INCENTIVE COMPENSATION RECOUPMENT POLICY

Exhibit 97.1 OPTHEA LIMITED INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Remuneration Committee (the “Remuneration Committee”) of the Board of Directors (the “Board”) of Opthea Limited, an Australian corporation (the “Company”), has determined that it is in the best interests of the Company and its shareholders including holders of its American Depository Shares to adopt this Incen

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED because IT IS BOTH (I) NOT MATERIAL AND (ii) IS THE TYPE OF INFORMATION THAT OPTHEA TREATS AS PRIVATE OR CONFIDENTIAL Amended And Restated Development Funding Agreement

Exhibit 4.19 Execution Version CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED because IT IS BOTH (I) NOT MATERIAL AND (ii) IS THE TYPE OF INFORMATION THAT OPTHEA TREATS AS PRIVATE OR CONFIDENTIAL Amended And Restated Development Funding Agreement by and between Opthea Limited Ocelot SPV LP, as Collateral Agent, and The Investors From Time To Time Party Hereto Dec

EX-99.1

Appendix 4E Preliminary Final Report OPTHEA LIMITED ABN 32 006 340 567 YEAR ENDED JUNE 30, 2024 RESULTS FOR ANNOUNCEMENT TO THE MARKET June 30, 2024 $ June 30, 2023 $ Movement % Results Revenues from ordinary activities 3,519,392 3,335,902 Up 5.

/s/ Peter Lang

Exhibit 12.2 CERTIFICATIONS I, Peter Lang, certify that: 1. I have reviewed this annual report on Form 20-F of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Exhibit 99.1 ASX, Nasdaq and Media Release 8 August 2024 Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 Melbourne, Australia, and Princeton, NJ, US, August 8, 2024- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retina

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board Dr. Arshad Khanani to chair the newly formed Medical Advisory Board

Exhibit 99.1 ASX, Nasdaq and Media Release 17 July 2024 Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board Dr. Arshad Khanani to chair the newly formed Medical Advisory Board Melbourne, Australia, and Princeton, NJ, July 17, 2024 - Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Announces Results of the A$55.9m (US$36.9m1) Retail Entitlement Offer New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail

Exhibit 99.1 ASX, Nasdaq and Media Release 15 July 2024 Opthea Announces Results of the A$55.9m (US$36.9m1) Retail Entitlement Offer New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placeme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in

Exhibit 99.1 ASX, Nasdaq and Media Release 9 July 2024 Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy Melbourne, Australia a

OPT / Opthea Limited - Depositary Receipt (Common Stock) / REGAL FUNDS MANAGEMENT PTY LTD - AMENDMENT NO. 4 Passive Investment

SC 13G/A 1 z72243sc13ga4.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value (Title of Class of Securities) 68386J208 (CUSIP Number) June

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

OptheaA$55.0m (US$36.9m1)Retail Entitlement Offer Opens Fullyunderwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m1) will close at 5:00 pm (Melbourn

Exhibit 99.1 ASX, Nasdaq and Media Release 19 June 2024 OptheaA$55.0m (US$36.9m1)Retail Entitlement Offer Opens Fullyunderwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m1) will close at 5:00 pm (Melbourne time) on 10 July 2024 Prospectus and personalized application forms to be dispatched to elig

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m1) Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 a

Exhibit 99.1 ASX, Nasdaq and Media Release 14 June 2024 Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m1) Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 Melbourne, Australia and Princeton, NJ, J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million1) Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of soziniberc

Exhibit 99.1 ASX, Nasdaq and Media Release 12 June 2024 Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million1) Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2 calendar year 20

Opthea Prospectus

Exhibit 99.1 ASX, NASDAQ and Media Release 12 June 2024 Opthea Prospectus Further to the announcements today, 12 June 2024 by Opthea Limited (ASX:OPT), Opthea attaches the Prospectus issued in connection with New Shares and New Options to be issued under its up to approximately A$217.3 million (US$143.4 million1) entitlement offer and Placement Options to be issued in connection with its up to A$1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Important Notice and Disclaimer IMPORTANT: You must read the following before continuing or making use of the information contained in this presentation. By attending an investor presentation, or accepting or viewing this presentation you represent a

Equity Raising Presentation Institutional Placement and Accelerated Non-Renounceable Entitlement Offer (“ANREO”) June 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Opthea To Present at Clinical Trials at the Summit Meeting

Exhibit 99.1 ASX, Nasdaq and Media Release 3 June 2024 Opthea To Present at Clinical Trials at the Summit Meeting Melbourne, Australia and Princeton, NJ, June 3, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degenerat

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b T

Exhibit 99.1 ASX, Nasdaq and Media Release 28 May 2024 Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal exe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal exe

Opthea Announces Upcoming Presentations at the Retina World Congress 2024

Exhibit 99.1 ASX, Nasdaq and Media Release 1 May 2024 Opthea Announces Upcoming Presentations at the Retina World Congress 2024 Melbourne, Australia and Princeton, NJ, May 1, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macu

Appendix 4C

Exhibit 99.1 ASX, Nasdaq and Media Release 30 April 2024 Quarterly Activity Report Q3 FY24 Highlights • Completion of enrolment in first trial of sozinibercept’s Phase 3 pivotal program (“COAST”) • Appointments of SVP Clinical Development and SVP Regulatory Affairs • Appointment of Dr. Arshad Khanani, MD, MA, FASRS as Chief Medical Advisor • On track to complete enrolment of the second Phase 3 piv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release 25 April 2024 Opthea to Present at the OIS Retina Innovation Summit at ARVO Melbourne, Australia and Princeton, NJ, April 25, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular de

Opthea Appoints John Han, PharmD, as VP Medical Affairs Brings extensive experience in retinal and ophthalmology diseases

Exhibit 99.1 ASX, Nasdaq and Media Release 9 April 2024 Opthea Appoints John Han, PharmD, as VP Medical Affairs Brings extensive experience in retinal and ophthalmology diseases Melbourne, Australia and Princeton, NJ, April 9, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release 5 April 2024 Opthea to Participate in the 23rdAnnual Needham Virtual Healthcare Conference Melbourne, Australia and Princeton, NJ, April 4, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-rela

Disclaimer This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”). This presentation is current

Transforming Patient Outcomes with Superior Vision Gains Corporate Presentation | April 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Appoints Sujal Shah to the Board of Directors Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair

Exhibit 99.1 ASX, Nasdaq and Media Release 4 April 2024 Opthea Appoints Sujal Shah to the Board of Directors Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Melbourne, Australia and Princeton, NJ, April 4, 2024 - Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceuti

Disclaimer This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”). This presentation is current

Transforming Patient Outcomes with Superior Vision Gains Virtual KOL Event | April 3, 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Exhibit 99.1 ASX, Nasdaq and Media Release 19 March 2024 Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024 Melbourne, Australia and Princeton, NJ, March 19, 2024 - Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Exhibit 99.1 ASX, Nasdaq and Media Release 06 March 2024 Opthea to Participate in the Leerink Partners Global Biopharma Conference Melbourne, Australia, 06 March 2024, and Princeton, New Jersey, 05 March 2024 – Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today annou

Disclaimer This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”). This presentation is current

Transforming Patient Outcomes with Superior Vision Gains Corporate Presentation | March 2024 NASDAQ (OPT); ASX (OPT.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

2024 Half year report OPTHEA February 29, 2024 Half-Year Financial Report December 31, 2023 In accordance with Listing Rule 4.2A, we enclose the Half-Year Financial Report (reviewed) on the consolidated results of Opthea Limited (“Opthea”, the “Group

Exhibit 99.2 2024 Half year report OPTHEA February 29, 2024 Half-Year Financial Report December 31, 2023 In accordance with Listing Rule 4.2A, we enclose the Half-Year Financial Report (reviewed) on the consolidated results of Opthea Limited (“Opthea”, the “Group” or the “Company”) for the half year ended December 31, 2023. The previous corresponding periods are the fiscal year ended June 30, 2023

Opthea Reports Half-Year Financial Results and Business Updates Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointmen

Exhibit 99.1 ASX, Nasdaq and Media Release 29 February 2024 Opthea Reports Half-Year Financial Results and Business Updates Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr. Frederic Guerard as CEO, Peter Lang as CFO, and Dr. Arshad M. Khanani as Chief M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor Global retina expert joins to support sozinibercept development and launch preparation

Exhibit 99.1 ASX, Nasdaq and Media Release 20 February 2024 Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor Global retina expert joins to support sozinibercept development and launch preparation Melbourne, Australia, 20 February, 2024 – Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly pr

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in

Exhibit 99.1 ASX, Nasdaq and Media Release 14 February 2024 Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 COAST and ShORe top-line results expected by mid-2025 Melbourne, Australi

OPT / Opthea Limited - Depositary Receipt (Common Stock) / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm242424d23sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 68386J208** (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

OPT / Opthea Limited - Depositary Receipt (Common Stock) / REGAL FUNDS MANAGEMENT PTY LTD - AMENDMENT NO. 3 Passive Investment

SC 13G/A 1 e214241sc13ga3.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value (Title of Class of Securities) 68386J208 (CUSIP Number) De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

OptheaStrengthens Team with Key Clinical and Regulatory Hires

Exhibit 99.1 ASX, Nasdaq and Media Release 01 February 2024 OptheaStrengthens Team with Key Clinical and Regulatory Hires Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st. Experienced executives bring extensive track record in products for retinal and ophthalmology diseases. Melbourne, Australia, 01 February, 2024 – Opthea Limited (ASX:OPT; NASDA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Disclaimer This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (“Opthea” or “Company”) and its affiliates and subsidiaries (together, the “Opthea Group”). The information contained in

Sozinibercept (OPT-302) for Wet AMD Transforming Patient Outcomes by Improving Vision Corporate Presentation | January 2024 OPTHEA.

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Exhibit 99.1 ASX, Nasdaq and Media Release 27 December 2023 Opthea to Receive US$35M Commitment and Additional US$50M Funding • Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor • This financing is non-dilutive to sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea Receives A$8.8 million R&D Tax Incentive

Exhibit 99.1 ASX, Nasdaq and Media Release 19 December 2023 Opthea Receives A$8.8 million R&D Tax Incentive Melbourne, Australia; 19 December 2023 – Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release 30 November 2023 Opthea Chairman’s Address to the 2023 Annual General Meeting Melbourne, Australia;30 November 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT) Good morning to those of you who have joined us from Australia and good afternoonto our US shareholders. On behalf of the board and management team I am pleased to report that we have made significant p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea to Present at the FLORetina 2023 Congress

Exhibit 99.1 ASX, Nasdaq and Media Release 30 November 2023 Opthea to Present at the FLORetina 2023 Congress Melbourne, Australia; 30 November 2023 – Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea to Present at the Jefferies 2023 London Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release November 9, 2023 Opthea to Present at the Jefferies 2023 London Healthcare Conference Melbourne, Australia; November 9, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Exhibit 99.1 ASX, Nasdaq and Media Release October 30, 2023 Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference Melbourne, Australia; October 30, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Meg

Opthea Appoint U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard ap

Exhibit 99.1 ASX, Nasdaq and Media Release October 27, 2023 Opthea Appoint U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter Lang appointed as CFO, bringing complementary expertise to lead O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

HOPE IS ON THE HORIZON NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY NOTES

HOPE IS ON THE HORIZON NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY NOTES Notice of Annual General Meeting and Explanatory Notes Date: Thursday, November 30, 2023 Time: 9:00am (Melbourne time) Location: The meeting will be held virtually via https://meetnow.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea to Participate at the 2023 Euretina Congress

Exhibit 99.1 ASX, Nasdaq and Media Release October 2, 2023 Opthea to Participate at the 2023 Euretina Congress Melbourne, Australia; October 2, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company’s Chief Execu

/s/ Megan Baldwin

Exhibit 12.1 CERTIFICATIONS I, Megan Baldwin, certify that: 1. I have reviewed this annual report on Form 20-F of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

OPTHEA US INC.

Exhibit 4.5 OPTHEA US INC. September 21, 2022 Tim Morris 2004 Oxford Ave Austin, Texas 78704 USA Re: Employment Terms Dear Tim On behalf of OPTHEA US, INC. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which is anticipated

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements No. 333-251052 on Form S-8 and No. 333-262444 on Form F-3, of our report dated September 28, 2023 relating to the financial statements of Opthea Limited appearing in this Annual Report on Form 20-F for the year ended June 30, 2023. /s/ Deloitte Touche Tohmat

/s/ Timothy Morris

Exhibit 12.2 CERTIFICATIONS I, Timothy Morris, certify that: 1. I have reviewed this annual report on Form 20-F of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th

EX-99.1

&! !$ƑƏƑƑ҄ƑƏƑƒ HOPE IS ON THE HORIZON Š b0 b|Ɩ Ɩ ĺƐOur cover Our lead drug candidate Sozinibercept Ő$ŊƒƏƑő-v|;ro|;m|b-Ѵ|o0;1ol; |;=buv|v;Ѵ;1|bˆ;(  ŋņ bmb0b|ou =ou|;|u;-|l;m|o=‰;| ĺ Contents 010o†|r|;- 02 Our Journey 04 "oŒbmb0;u1;r|uo]u;vvbm]bmѴo0-Ѵ‰;| -v;ƒ$ub-Ѵv 06 uĺ-uѴ;v)‹ho== 08 uo=;vvou$blo|‹-1hvom 10 -bul-mĽv;||;u 12  Ľv;||;u

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Megan Baldwin, Chief Executive Officer of Opthea Limited (the “Company”), and Timothy Morris, Chief Financial Officer of the Company, each hereby certifies

Opthea Limited, Suite 0403, Level 4, 650 Chapel Street, South Yarra, Victoria 3141, Australia Phone: +61 3 9826 0399 / Fax: +61 3 9824 0083

Exhibit 4.16 Consultancy Agreement Opthea Limited Mr Lawrence Gozlan (Consultant) Details Date 24 August 2023 Parties Name Opthea Limited ABN 32 006 340 567 Short form name Opthea Notice details Attn: Dr. Megan Baldwin Address: Suite 0403, Level 4, 650 Chapel Street South Yarra Vic 3141 Australia Name Mr Lawrence Gozlan Short form name Consultant Notice details Attn: Mr Lawrence Gozlan Email: lawr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File No. 001-39621 OPTHEA LI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s princip

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Exhibit 99.1 ASX, Nasdaq and Media Release September 7, 2023 Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference Melbourne, Australia; September 7, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-396

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia (Address of principal

Appendix 4E

Exhibit 99.2 Appendix 4E Preliminary Final Report OPTHEA LIMITED ABN 32 006 340 567 YEAR ENDED JUNE 30, 2023 RESULTS FOR ANNOUNCEMENT TO THE MARKET June 30, 2023 $ June 30, 2022 $ Movement % Results Revenues from ordinary activities 108,406 90,683 Up 19.5% Loss from ordinary activities after tax attributable to members (142,521,085 ) (92,817,371 ) Loss has increased 53.6% Loss for the year attribu

Opthea Retail Entitlement Offer Opens

EX-99.1 Exhibit 99.1 ASX, Nasdaq and Media Release 31 August 2023 Opthea Retail Entitlement Offer Opens • On Monday, 28 August 2023 OPT announced that it had successfully completed the placement and institutional entitlement offer components of its previously announced capital raising. • The fully underwritten Retail Entitlement Offer to raise a further approximately A$16.3m will open today, Thurs

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million1)

Exhibit 99.1 ASX, Nasdaq and Media Release 28 August 2023 Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million1) • OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raising • As a result of strong demand from both existing and new domestic and offshore institutional

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-396

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia (Address of princ

Opthea Limited ACN 006 340 567

EX-99.3 Exhibit 99.3 Opthea Limited ACN 006 340 567 Prospectus For the offer of: • approximately 35.9 million New Shares at the Offer Price of $0.46 per New Share and approximately 18.0 million New Options to Eligible Shareholders with an exercise price of $0.80 under the Retail Entitlement Offer on the basis of 1 New Option for every 2 New Shares issued under the Retail Entitlement Offer; and • a

Opthea announces Placement and fully underwritten Entitlement Offer to raise A$80.0 million (US$51.2 million1)

EX-99.2 Exhibit 99.2 ASX, Nasdaq and Media Release 24 August 2023 Opthea announces Placement and fully underwritten Entitlement Offer to raise A$80.0 million (US$51.2 million1) Melbourne, Australia; 24 August 2023 – Opthea Limited (Opthea or the Company) (ASX:OPT; NASDAQ:OPT), (Opthea, OPT or the Company) a clinical stage biopharmaceutical company developing novel therapies to treat highly prevale

Important Notice and Disclaimer IMPORTANT: You must read the following before continuing or making use of the information contained in this presentation. By attending an investor presentation, or accepting or viewing this presentation you represent a

EX-99.1 Equity Raising Presentation Institutional Placement and Accelerated Non-Renounceable Entitlement Offer (“ANREO”) August 2023 OPTHEA.COM | @OptheaLimited | ASX (OPT.AX); NASDAQ: OPT Exhibit 99.1 Important Notice and Disclaimer IMPORTANT: You must read the following before continuing or making use of the information contained in this presentation. By attending an investor presentation, or ac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-396

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia (Address of princ

Disclosures Presenter’s Financial Disclosures: - Adverum (C), Gemini, Genentech, Inc., Iveric Bio, NGM, Opthea (C), Regeneron, Regenxbio • This presentation will discuss IRB/IEC approved research of an investigational product. (C): Consultant; (S): S

Population Pharmacokinetics and Safety of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases Dante J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-39621 OPTHEA LIMIT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Exhibit 99.1 ASX, Nasdaq and Media Release July 26, 2023 Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302 Melbourne, Australia; July 26, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association’s Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Exhibit 99.1 ASX, Nasdaq and Media Release July 24, 2023 Opthea to Present at the 2023 Ophthalmology Innovation Summit Melbourne, Australia; July 24, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Exhibit 99.1 ASX, Nasdaq and Media Release July 10, 2023 Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting • Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases • Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD hosted by Oppenheimer & Co. Melbourne, Australia; July 1

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Exhibit 99.1 ASX, Nasdaq and Media Release July 10, 2023 Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor Melbourne, Australia; July 10, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today the resignation of Dr. Joel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release June 8, 2023 Opthea Appoints Anshul Thakral as Non-Executive Director of the Board Melbourne, Australia; June 8, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal ex

Opthea to Present at the Jefferies 2023 Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release May 25, 2023 Opthea to Present at the Jefferies 2023 Healthcare Conference Melbourne, Australia; May 25, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal exe

Opthea to Particpate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market

Exhibit 99.1 ASX, Nasdaq and Media Release May 17, 2023 Opthea to Particpate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market Melbourne, Australia; May 17, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal exe

Opthea To Present at the JMP Securities Life Sciences Conference

Exhibit 99.1 ASX, Nasdaq and Media Release May 8, 2023 Opthea To Present at the JMP Securities Life Sciences Conference Melbourne, Australia; 8 May 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financial Officer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal exe

Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ

Exhibit 99.1 ASX, Nasdaq and Media Release April 28, 2023 Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ Melbourne, Australia; April 28, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea Receives A$8.7 million R&D Tax Incentive

Exhibit 99.1 ASX, Nasdaq and Media Release March 7, 2023 Opthea Receives A$8.7 million R&D Tax Incentive Melbourne, Australia; 7 March 2023 – Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million (US$6.3 million) research and develo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-39621 OPTHEA LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal e

Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference

Exhibit 99.1 ASX, Nasdaq and Media Release March 6, 2023 Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference Melbourne, Australia; March 6, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release February 23, 2023 Opthea Limited / 2023 HALF-YEAR REPORT logo February 23, 2023 Half-Year Financial Report December31, 2022 In accordancewith Listing Rule 4.2A, we enclose the Half-Year FinancialReport (reviewed) on the consolidated results of Opthea Limited (“Opthea”,the “Group” or the “Company”)for the half year ended December 31, 2022. The previous cor

OPT / Opthea Limited ADS / VGI Partners Ltd - FORM SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value (Title of Class of Securities) 68386J208 (CUSIP Number) December 31, 2022 (Date of Event which Requires Fi

OPT / Opthea Limited ADS / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm234999d22sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opthea Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 68386J208** (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology

EX-99 2 opt-ex991.htm PRESS RELEASE Exhibit 99.1 ASX, Nasdaq and Media Release February 13, 2023 Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology Melbourne, Australia; 13 February, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIM

6-K 1 opt6-koptheaph2bres.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia

Opthea To Present at SVB Leerink Global Biopharma Conference

Exhibit 99.1 ASX, Nasdaq and Media Release February 6, 2023 Opthea To Present at SVB Leerink Global Biopharma Conference Melbourne, Australia; 6 February, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principa

Opthea To Present at Sequire Biotechnology Conference

Exhibit 99.1 ASX, Nasdaq and Media Release January 30, 2023 Opthea To Present at Sequire Biotechnology Conference Melbourne, Australia; 30 January, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Disclaimer This presentation includes general background information about the activities of Opthea Limited (ABN 32 006 340 567) (‘Opthea’ or ‘Company’) and its affiliates and subsidiaries (together, the ‘Opthea Group’). The information contained in

Leading Therapeutic Innovation in Retinal Diseases Corporate Presentation January 2023 Megan Baldwin, Chief Executive Officer Timothy Morris, Chief Financial Officer OPTHEA.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant’s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant’s principal

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

Exhibit 99.1 ASX, Nasdaq and Media Release December 12, 2022 Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD Melbourne, Australia; 12 December, 2022 ? Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an ?Ask

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant?s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant?s principa

Opthea to Present at the FLORetina 2022 Congress

Exhibit 99.1 ASX, Nasdaq and Media Release December 6, 2022 Opthea to Present at the FLORetina 2022 Congress Melbourne, Australia; 6 December, 2022 ? Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress, taking

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-39621 OPTHEA LIM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant?s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant?s principa

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release 16 November 2022 Opthea Chairman?s Address to the 2022 Annual General Meeting Melbourne, Australia; 16 November 2022 ? Opthea Limited (NASDAQ:OPT; ASX:OPT) Good morning to those of you who have joined us from Australia and good afternoon to our US shareholders. On behalf of the board and management team I am pleased to report that we have continued to mak

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39621 OPTHEA LIMITED (Translation of registrant?s name into English) Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia (Address of princip

Opthea Limited, Suite 0403, Level 4, 650 Chapel Street, South Yarra, Victoria 3141, Australia A.C.N. 006 340 567 l Telephone: +61 3 9826 0399 l Website: www.opthea.com

Exhibit 99.2 16 November 2022 Market Announcements Office Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000 Dear Ms, Results of 2022 Annual General Meeting Opthea Limited (ASX: OPT) In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the att

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39621 OPTHEA LIMITED (Translation of registrant?s name into English) Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia (Address of princip

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release 10 November 2022 Opthea to Present at Jefferies London Healthcare Conference Melbourne, Australia; 10 November, 2022 ? Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File No. 001-39621 OPTHEA LIMI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant?s name into English) Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant?s principal

ASX, Nasdaq and Media Release

Exhibit 99.1 ASX, Nasdaq and Media Release October 24, 2022 Melbourne, Australia; 24 October 2022 ? Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer (CFO), effective 24 October 2022. Mr. Morris

Consent of Deloitte Touche Tohmatsu, independent registered public accounting firm.

EX-15.1 9 opt-ex15113.htm EX-15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements No. 333-251052 on Form S-8 and No. 333-262444 on Form F-3, of our report dated September 29, 2022 relating to the financial statements of Opthea Limited appearing in this Annual Report on Form 20-F for the year ended June 30

Executive Employment Contract, dated December 31, 2021, between Opthea US Inc and Judith Robertson.

Exhibit 4.11 Ms Judy Robertson December 31, 2021 OPTHEA US INC. December 31, 202J Judy Robertson 687 Princeton Ave Brick, New Jersey Re: Employment Terms Dear Ms. Robertson, On behalf of OPTHEA US, INC. (the"Company"), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the "Agreement''). As discussed, the terms of this Agreement. govern with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Development Funding Agreement by and between Opthea Limited and Ocelot SPV LP dated August 12, 2022

Execution Version Exhibit 4.14 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED because IT IS BOTH (I) NOT MATERIAL AND (ii) IS THE TYPE OF INFORMATION THAT OPTHEA TREATS AS PRIVATE OR CONFIDENTIAL Development Funding Agreement by and between Opthea Limited and Ocelot SPV LP August 12, 2022 Execution Version DEVELOPMENT FUNDING AGREEMENT This Development Funding Ag

Certification of the Principal Executive Officer pursuant to rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 12.1 CERTIFICATIONS I, Megan Baldwin, certify that: 1. I have reviewed this annual report on Form 20-F of Opthea Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the